Literature DB >> 19051265

Serum BLyS levels increase after rituximab as initial therapy in patients with follicular Grade 1 non-Hodgkin lymphoma.

Stephen M Ansell1, Anne J Novak, Steven Ziesmer, Tammy Price-Troska, Betsy LaPlant, Stacey R Dillon, Thomas E Witzig.   

Abstract

Serum B-lymphocyte stimulator (BLyS) levels are elevated in a subset of non-Hodgkin lymphoma (NHL) patients, particularly those with a family history of B-cell malignancies or a polymorphism in the BLyS gene. BLyS promotes growth of malignant B-cells and increased serum BLyS levels are associated with a poor clinical outcome. In this study, BLyS levels were measured before and after 4 weekly doses of rituximab in 30 patients with previously untreated follicular Grade 1 NHL. A significant increase was seen in the serum levels of BLyS (P = 0.0001) after rituximab therapy. The increase was independent of genetic variability in the BLyS gene.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19051265      PMCID： PMC2774736          DOI： 10.1002/ajh.21328

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


  22 in total

1.  BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF.

Authors:  J S Thompson; S A Bixler; F Qian; K Vora; M L Scott; T G Cachero; C Hession; P Schneider; I D Sizing; C Mullen; K Strauch; M Zafari; C D Benjamin; J Tschopp; J L Browning; C Ambrose
Journal:  Science       Date:  2001-08-16       Impact factor: 47.728

2.  TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease.

Authors:  J A Gross; J Johnston; S Mudri; R Enselman; S R Dillon; K Madden; W Xu; J Parrish-Novak; D Foster; C Lofton-Day; M Moore; A Littau; A Grossman; H Haugen; K Foley; H Blumberg; K Harrison; W Kindsvogel; C H Clegg
Journal:  Nature       Date:  2000-04-27       Impact factor: 49.962

3.  Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation.

Authors:  P Colombat; G Salles; N Brousse; P Eftekhari; P Soubeyran; V Delwail; E Deconinck; C Haïoun; C Foussard; C Sebban; A Stamatoullas; N Milpied; F Boué; B Taillan; P Lederlin; A Najman; C Thièblemont; F Montestruc; A Mathieu-Boué; A Benzohra; P Solal-Céligny
Journal:  Blood       Date:  2001-01-01       Impact factor: 22.113

4.  TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS.

Authors:  J A Gross; S R Dillon; S Mudri; J Johnston; A Littau; R Roque; M Rixon; O Schou; K P Foley; H Haugen; S McMillen; K Waggie; R W Schreckhise; K Shoemaker; T Vu; M Moore; A Grossman; C H Clegg
Journal:  Immunity       Date:  2001-08       Impact factor: 31.745

5.  Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma.

Authors:  John D Hainsworth; Sharlene Litchy; Howard A Burris; Daniel C Scullin; Steven W Corso; Denise A Yardley; Lisa Morrissey; F Anthony Greco
Journal:  J Clin Oncol       Date:  2002-10-15       Impact factor: 44.544

6.  Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI.

Authors:  S A Marsters; M Yan; R M Pitti; P E Haas; V M Dixit; A Ashkenazi
Journal:  Curr Biol       Date:  2000-06-29       Impact factor: 10.834

7.  Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL.

Authors:  Bing He; Amy Chadburn; Erin Jou; Elaine J Schattner; Daniel M Knowles; Andrea Cerutti
Journal:  J Immunol       Date:  2004-03-01       Impact factor: 5.422

Review 8.  BAFF: a fundamental survival factor for B cells.

Authors:  Fabienne Mackay; Jeffrey L Browning
Journal:  Nat Rev Immunol       Date:  2002-07       Impact factor: 53.106

Review 9.  First-line and maintenance treatment with rituximab for patients with indolent non-Hodgkin's lymphoma.

Authors:  John D Hainsworth
Journal:  Semin Oncol       Date:  2003-02       Impact factor: 4.929

10.  Increased serum BAFF (B-cell activating factor of the TNF family) level is a peculiar feature associated with familial chronic lymphocytic leukemia.

Authors:  Stefano Molica; Giovanna Digiesi; Francesca Mauro; Rosanna Mirabelli; Giovanna Cutrona; Gaetano Vitelli; Fortunato Morabito; Francesco Iuliano; Robin Foà; Manlio Ferrarini
Journal:  Leuk Res       Date:  2008-06-16       Impact factor: 3.156
View more
  8 in total

1.  Comprehensive serum cytokine analysis identifies IL-1RA and soluble IL-2Rα as predictors of event-free survival in T-cell lymphoma.

Authors:  M Gupta; M Stenson; M O'Byrne; M J Maurer; T Habermann; J R Cerhan; G W Weiner; T E Witzig
Journal:  Ann Oncol       Date:  2015-10-20       Impact factor: 32.976

2.  Elevated serum levels of B-cell activating factor in pediatric renal transplant patients.

Authors:  Anja Lehnhardt; Franziska Dunst; Michael van Husen; Sebastian Loos; Jun Oh; Thomas Eiermann; Martina Koch; Markus J Kemper
Journal:  Pediatr Nephrol       Date:  2012-03-28       Impact factor: 3.714

3.  B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin.

Authors:  Stacey R Dillon; Brandon Harder; Kenneth B Lewis; Margaret D Moore; Hong Liu; Thomas R Bukowski; Nels B Hamacher; Megan M Lantry; Mark Maurer; Cecile M Krejsa; Jeff L Ellsworth; Susan Pederson; Keith B Elkon; Mark H Wener; Maria Dall'Era; Jane A Gross
Journal:  Arthritis Res Ther       Date:  2010-03-19       Impact factor: 5.156

4.  Living life without B cells: is repeated B-cell depletion a safe and effective long-term treatment plan for rheumatoid arthritis?

Authors:  David R Chen; Philip L Cohen
Journal:  Int J Clin Rheumtol       Date:  2012-04-01

5.  APRIL and BAFF: novel biomarkers for central nervous system lymphoma.

Authors:  Matthias Mulazzani; Marion Huber; Sabine Borchard; Sigrid Langer; Barbara Angele; Elisabeth Schuh; Edgar Meinl; Martin Dreyling; Tobias Birnbaum; Andreas Straube; Uwe Koedel; Louisa von Baumgarten
Journal:  J Hematol Oncol       Date:  2019-10-15       Impact factor: 17.388

6.  Serum soluble TACI, a BLyS receptor, is a powerful prognostic marker of outcome in chronic lymphocytic leukemia.

Authors:  Marie-Christine Kyrtsonis; Katerina Sarris; Efstathios Koulieris; Dimitrios Maltezas; Eftychia Nikolaou; Maria K Angelopoulou; Vassiliki Bartzis; Tatiana Tzenou; Maria Dimou; Mariana P Siakandaris; Nora A Viniou; Sotirios Sachanas; Christina Kalpadakis; Petros P Sfikakis; Gerassimos A Pangalis; Panayiotis Panayiotidis
Journal:  Biomed Res Int       Date:  2014-08-06       Impact factor: 3.411

7.  Association of variants in BAFF (rs9514828 and rs1041569) and BAFF-R (rs61756766) genes with the risk of chronic lymphocytic leukemia.

Authors:  Monika Jasek; Agnieszka Bojarska-Junak; Marta Wagner; Maciej Sobczyński; Dariusz Wołowiec; Jacek Roliński; Lidia Karabon; Piotr Kuśnierczyk
Journal:  Tumour Biol       Date:  2016-07-29

8.  Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study.

Authors:  David Jayne; Daniel Blockmans; Raashid Luqmani; Sergey Moiseev; Beulah Ji; Yulia Green; Leanne Hall; David Roth; Robert B Henderson; Peter A Merkel
Journal:  Arthritis Rheumatol       Date:  2019-04-16       Impact factor: 10.995
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.